FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

_		
Vashington.	D.C. 20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BVF PARTNERS L P/IL					2. Issuer Name and Ticker or Trading Symbol  Kymera Therapeutics, Inc. [ KYMR ]								(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last) 44 MON	(F TGOMERY	irst) Y STREET	(Middle)			Date 6/18/2		t Tran	saction (Mon	th/D	ay/Year)							- below)	·	
40TH FLOOR  (Street) SAN FRANCISCO CA 94104			- 4.	If Am	endment,	Date	of Original Fi	led (	Month/Da	Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person									
(City) (State) (Zip)			_   R	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Ta	ble I - Non	-Deri	ivativ	re Se	ecuritie	s A	cquired, D	)isp	osed o	of, or E	Bene	ficially	/ Owned					
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (In	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)		(A) or 3, 4 and	5. Amoun Securities Beneficia Owned Fo	Form: Direct ly (D) or Indirect		: Direct r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common	Stock \$0.0	0001 par value <sup>(1)</sup>							Code	v	Amount	(A (D	) or )	Price	Transaction(s) (Instr. 3 and 4)			D <sup>(2)</sup>		
		0001 par value <sup>(1)</sup>													2,104			D <sup>(3)</sup>		
		0001 par value <sup>(1)</sup>										+				294,632		D <sup>(4)</sup>		
			Table II - I												Owned		<u> </u>			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate,	4. Transa Code ( 8)	ction	5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve ies ed ed nstr.	6. Date Exer Expiration D (Month/Day/	cisal ate	ole and	7. Title a of Secu Underly Derivati	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	vative urities leficially ned owing overted osaction(s)  Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Ex Da	piration ate	Title	or Nu	mount umber Shares						
Stock Option (Right to Buy) <sup>(5)</sup>	\$31.2	06/18/2024			A		16,000		(6)	06	/17/2034	Commo Stock, \$0.0000 par valu	1	6,000	\$0.00	16,00	0	I <sup>(5)</sup>	See footnote <sup>(5)</sup>	
Pre- Funded Warrants to Purchase Common Stock <sup>(1)</sup>	\$0.0001								(7)		(7)	Commo Stock, \$0.000 par valu	5.5	50,425		550,42	25	D <sup>(2)</sup>		
Pre- Funded Warrants to Purchase Common Stock <sup>(1)</sup>	\$0.0001								(7)		(7)	Commo Stock, \$0.000 par valu	31	75,856		375,856		D(3)		
Pre- Funded Warrants to Purchase Common Stock <sup>(1)</sup>	\$0.0001								(7)		(7)	Commo Stock, \$0.0000 par valu	5	2,733		52,73	3	D <sup>(4)</sup>		
Stock Option (Right to Buy) <sup>(5)</sup>	\$20								(8)	08	/19/2030	Commo Stock, \$0.000 par valu	4	0,127		40,12	7	I <sup>(5)</sup>	See footnote <sup>(5)</sup>	
Stock Option (Right to Buy) <sup>(5)</sup>	\$49.1								(8)	06	/15/2031	Commo Stock, \$0.000 par valu	2	0,063		20,06	3	I <sup>(5)</sup>	See footnote <sup>(5)</sup>	
Stock Option (Right to Buy) <sup>(5)</sup>	\$14.18								(8)	06	/14/2032	Commo Stock, \$0.000 par valu	1	2,000		12,00	0	I <sup>(5)</sup>	See footnote <sup>(5)</sup>	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Day/\(\text{Month/Day/\}\)	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy) <sup>(5)</sup>	\$27.67							(8)	06/14/2033	Common Stock, \$0.0001 par value	12,000		12,000	I(2)
	nd Address of	Reporting Person*												
(Last) 44 MON 40TH FI	TGOMERY	(First) Y STREET	(Middle)		_									
(Street)	ANCISCO	CA	94104		_									
(City)		(State)	(Zip)		-									
		Reporting Person*												
(Last) 44 MON 40TH FI	TGOMERY LOOR	(First) Y STREET	(Middle)											
(Street) SAN FR	ANCISCO	CA	94104		_									
(City)		(State)	(Zip)		-									
	nd Address of	Reporting Person*												
(Last) 44 MON 40TH FI	TGOMERY LOOR	(First) Y STREET	(Middle)											
(Street) SAN FR	ANCISCO	CA	94104		_									
(City)		(State)	(Zip)											
		Reporting Person*	E FUND II LI	)										
(Last) 44 MON 40TH FI	TGOMERY LOOR	(First) Y STREET	(Middle)											
					_									
(Street) SAN FR	ANCISCO	CA	94104											

(Last)

(Street)

(City)

40TH FLOOR

(First)

(State)

44 MONTGOMERY STREET

SAN FRANCISCO CA

(Middle)

94104

(Zip)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

footnote<sup>(5)</sup>

1. Name and Address o	f Reporting Person*	
Biotechnology Y	Value Trading Fur	nd OS LP
(Last)	(First)	(Middle)
P.O. BOX 309 UGL	,	(ivildule)
1.0. BOX 309 OGI	LAND HOUSE	
(Street)		
GRAND	E9	KY1-1104
CAYMAN		
(City)	(State)	(Zip)
1. Name and Address o BVF Partners O	· -	
(Last)	(First)	(Middle)
P.O. BOX 309 UGL		(Middle)
1.0. BOX 307 CGI	IND HOUSE	
(Street)		
GRAND	E9	KY1-1104
CAYMAN		
(City)	(State)	(Zip)
Name and Address o	f Reporting Person*	
BVF GP HOLD	, •	
(Last)	(First)	(Middle)
44 MONTGOMER	Y STREET	
40TH FLOOR		
(0)		
(Street) SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address o <u>BVF INC/IL</u>	f Reporting Person <sup>*</sup>	
(Last)	(Eiret)	(Middle)
(Last) 44 MONTGOMER	(First) Y STREET	(Middle)
40TH FLOOR		
(Street)		04104
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Address o LAMPERT MA		
(Lost)	(First)	(Middle)
(Last) 44 MONTGOMER	(First)	(Middle)
40TH FLOOR	I SINEE1	
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
Explanation of Respon		• •

## Explanation of Responses:

- 1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its person in the securities of the securities reported herein except to the extent of his or its person in the securities of the securities reported herein except to the extent of his or its person in the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities reported herein except to the extent of his or its person is a member of the securities and the securities are the securities of the securities and the securities are the securities are the securities are the securities are the securitie
- 2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- 3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- 4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- 5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the

securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

- 6. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders.
- 7. The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.
- 8. The shares subject to the option have fully vested.

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/28/2024
Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer	06/28/2024
BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/28/2024
Biotechnology Value Fund II, L.P., By; BVF II GP LLC, its general partner, By; /s/ Mark N. Lampert, Chief Executive Officer	06/28/2024
BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/28/2024
BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President	06/28/2024
Biotechnology Value Trading Fund OS LP, By; BVF Partners L.P., its investment manager, BVF Inc., its general partner, By; /s/ Mark N, Lampert, President	06/28/2024
BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer	06/28/2024
BVF Inc., By: /s/ Mark N. Lampert, President	06/28/2024
/s/ Mark N. Lampert ** Signature of Reporting Person	$\frac{06/28/2024}{\text{Date}}$

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).